Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SCPH = Mcap $190 M / Cash $120 M / FDA Decision for potential Blockbuster Drug next Quarter ($7 BILLION Market)/ MASSIVE insider buying =Undiscovered low float gem with 1000% Upside
Presentation
https://scpharmaceuticalsinc.gcs-web.com/static-files/97f71625-1751-4ea3-8376-5030dbe85508
SCPH = Mcap $190 M / Cash $120 M / FDA Decision for potential Blockbuster Drug next Quarter ($7 BILLION Market)/ MASSIVE insider buying =Undiscovered low float gem with 1000% Upside
https://scpharmaceuticalsinc.gcs-web.com/static-files/97f71625-1751-4ea3-8376-5030dbe85508
SCPH = Mcap $190 M / Cash $120 M / FDA Decision for potential Blockbuster Drug next Quarter ($7 BILLION Market)/ MASSIVE insider buying =Undiscovered low float gem with HUGE upside
https://scpharmaceuticalsinc.gcs-web.com/static-files/97f71625-1751-4ea3-8376-5030dbe85508
PBF next SPI the book value is around $20 PER share while trading at laughable $6.50
$900 MILLION Debt = Next BANKRUPT junk here
BOOK VALUE minus -$5.75 /$880 MILLINON DEBT = Bankrupt candidate
MEGA Debt of $7 BILLION / Burning massive Cash and Running out of Cash = Chapter 11 and Delisting on the way
$3 BILLION Debt / Book Value -$15.50 / Running out of Cash ..Looks great short gem here
WAVE.V =MC $8 M /2 MEGA CANCER Drug Approvals IMMINENT in Q4 for the US and European markets . Company has already 5x APPROVED Cancer Drugs for EU markets 2 of them jsut approved in last 2 weeks . This COMPLETE unknown Company is close to profitability . This stock is what i call A ONCE in A LIFETIME OPP guys market cap of C$ 8 million is more than just a PURE GIFT .
Waverley Pharma (WAVE.V) canadian company
Waverley Pharma Announces Grant of Market Authorization of Pemetrexed and Bortezomib in Multiple European Countries.. July 30, 2020
https://www.waverleypharma.com/uploads/3/8/0/2/38024367/waverley_pharma_-_press_release_-_july_30_2020.pdf
Pipeline
https://www.waverleypharma.com/generic-product-pipeline.html
WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAV-102 is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates yearly revenue of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAVE.V =MC $8 M /2 MEGA CANCER Drug Approvals IMMINENT in Q4 for the US and European markets . Company has already 5x APPROVED Cancer Drugs for EU markets 2 of them jsut approved in last 2 weeks . This COMPLETE unknown Company is close to profitability . This stock is what i call A ONCE in A LIFETIME OPP guys market cap of C$ 8 million is more than just a PURE GIFT .
Waverley Pharma (WAVE.V) canadian company
Waverley Pharma Announces Grant of Market Authorization of Pemetrexed and Bortezomib in Multiple European Countries.. July 30, 2020
https://www.waverleypharma.com/uploads/3/8/0/2/38024367/waverley_pharma_-_press_release_-_july_30_2020.pdf
Pipeline
https://www.waverleypharma.com/generic-product-pipeline.html
WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAV-102 is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates yearly revenue of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAVE.V =MC $8 M /2 MEGA CANCER Drug Approvals IMMINENT in Q4 for the US and European markets . Company has already 5x APPROVED Cancer Drugs for EU markets 2 of them jsut approved in last 2 weeks . This COMPLETE unknown Company is close to profitability . This stock is what i call A ONCE in A LIFETIME OPP guys market cap of C$ 8 million is more than just a PURE GIFT .
Waverley Pharma (WAVE.V) canadian company
Waverley Pharma Announces Grant of Market Authorization of Pemetrexed and Bortezomib in Multiple European Countries.. July 30, 2020
https://www.waverleypharma.com/uploads/3/8/0/2/38024367/waverley_pharma_-_press_release_-_july_30_2020.pdf
Pipeline
https://www.waverleypharma.com/generic-product-pipeline.html
WAV-101 is an injectable generic chemotherapy drug development for the treatment of non-small cell lung cancer and other indications. Currently there is no marketed generic version for this product in the United States, and the brand generates yearly revenue of over $1 billion USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
WAV-102 is an injectable generic chemotherapy drug developed for the treatment of multiple myeloma and other indications. Currently there is no marketed generic for this product and the brand generates yearly revenue of over $800 million USD. Since regulatory filings have been made in the United States and Europe, Waverley Pharma is seeking a sales and marketing partner for Europe.
BCTXF =MC $4 M--O/S 722K shares / CHEAPEST Covid 19 Gem out there ...Next 10++Bagger or more EXPLODINGGGGGGGGG
Presentation
https://briacell.com/wp-content/uploads/2020/06/BriaCell-Investor-Presentation-2020June11.pdf
BCTXF =MCap $3 Million/O/S 722K shares /CHEAPEST Covid 19 Vaccine Gem /EXTREME low float / UNDISCOVERED stock =Potential 10+ Bagger UPSIDE RALLYYYYYYYYYYYYYYYYYY
Presentation
https://briacell.com/wp-content/uploads/2020/06/BriaCell-Investor-Presentation-2020June11.pdf
SNGX =EXPLODING after positive Covid 19 results
https://www.prnewswire.com/news-releases/soligenix-announces-publication-of-positive-pre-clinical-results-for-a-novel-covid-19-vaccine-301100798.html
Dilution could destroy this one , cash balance shows no no money so offering could happen any time